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Abstract

Langerhans cells (LC) are bone marrow derived residents of
the epidermis which

express the

CDIa surface

antigen

and

undergo a variety of phenotypic and functional changes in vitro.
To determine the effects of the epidermally associated cytokines
granulocyte

macrophage

colony-stimulating

factor

(GM-CSF),

Tumor Necrosis Factor-a (TNF-a), and lnterleukin-1 (IL-1) on LC
phenotype in vitro, epidermal cells were cultured in the presence
of these cytokines and the percentage of cells expressing CDIa
was

determined

by

flow

cytometry.

By

the

fifth

day,

the

percentage of cells expressing CDIa in TNF-a and control cultures
was about half of the starting value, while in IL-1 and GM-CSF
cultures CDIa expression was respectively higher and lower than
control.

To determine if these effects on CDIa expression are

generalizable, expression of CDIa by human cortical thymocytes
was

also

studied.

GM-CSF

thymocyte CDIa expression.
opposite

effects

on

class

decreased

and

IL-1

increased

In additon, these two cytokines had
I

major

histocompatibility

complex

(MHC) protein expression, suggesting that these two antigens are
reciprocally regulated.
with

function,

LC

To correlate these phenotypic changes

precultured
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with

cytokines were tested

for

their ability to stimulate allogeneic T-cell proliferation.

GM-CSF

treated cultures caused 2 to 3 times more T-cell proliferation
than control cultures.

Addition of antibodies reactive with class

I and class II MHC molecules blocked T-cell proliferation while
antibodies to CDIa did not.

We conclude that GM-CSF, a cytokine

that is produced by keratinocytes and thymic nonlymphoid cells in
vitro, can decrease CDIa expression by thymocytes and LC, while
increasing class I MHC expression by thymocytes.

Furthermore,

GM-CSF enhances the ability of human LC to stimulate allogeneic
reactions

in vitro.

This ability can be blocked by antibodies to

both class I and class II MHC molecules.

Introduction

Langerhans cells (LC) are a minor population of epidermal
cells that have been the subject of a large body of research since
their discovery by Paul Langerhans in 1868.

Langerhans believed

that the dendritic cells he had discovered with gold chloride
staining

were

intraepithelial

receptors

for

extracutaneous

signals to the nervous system [1], and such a theory prevailed for
a century.

In 1968, however, Breathnach et al proved that murine

Langerhans

cells

demonstrating

that

do

not

murine

originate
skin

components still contained LC [2].
out

by

Frelinger

et

al

using

4

in

the

deprived

of

neural
its

crest,

neural

by

crest

Further experiments carried
murine

radiation

chimeras

reconstituted with allogeneic bone marrow demonstrated that LC
originate in bone marrow [3].
similar

experiments

by

These findings were confirmed in

Katz

et

al

in

the

same

year

[4].

Subsequent studies in humans after male to female bone marrow
transplantation,

have

human

demonstrating

LC

by

established
the

the

bone

marrow

presence

of

origin

of

exclusively

Y

chromosome-positive LC (donor LC) in the skin biopsies of female
bone marrow transplant recipients [5,6].
During the 1970's a large body of evidence accumulated that
phenotypically linked LC to cells of the macrophage/monocyte
lineage.

Both types of cells express Fc and C3 receptors [7], HLA-

DR (Class il major histocompatibility complex) molecules [8,9],
membrane ATPase activity [11], and have the ability to migrate
[10].

Based on these findings, as well as ultrastructural evidence

[12,13], Katz et al has suggested that monocytes are the most
likely precursors of epidermal LC [4], however formal proof of a
specific LC precursor is lacking.
In

contrast

macrophage/monocytes,

to

the

similarities

several

between

phenotypic

and

LC

and

structural

features distinguish LC from all other cells studied to date.

Most

striking of these features is a cytoplasmic structure known as
the Birbeck granule.

In 1961, Birbeck published the first electron

micrographs of epidermal LC in which a unique membrane bound
granule

was

observed.

Birbeck

described

this

cytoplasmic

granule as a linear structure with rounded ends and a striated
line running down the center [14].
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This is the typical "tennis

racket" shape that is usually associated with Birbeck granules.
Recent evidence has suggested that these granules are involved in
receptor mediated endocytosis along with lysosomes, coated pits,
and coated vesicles [15,16,36], and they remain the gold standard
for the identification of epidermal LC.
Epidermal LC are also unique in their surface antigen profile.
As mentioned above, they express class II MHC protiens, however,
there is controversy as to whether they express very low levels
of class I MHC molecules [17,71], or are totally deficient in class
I MHC protein expression [18,19].

This relative lack of class I

MHC protein expression by LC is quite unusual and is shared only
with certain subsets of cortical thymocytes [37].

In addition, LC

express the CDIa surface antigen which is a glycoprotein with a
relative mass of 49,000 [20,21].

CDIa has also been called "T6"

because it is recognized by the OKT6 monoclonal antibody [21],
and is biochemically identical to Human Thymocyte Antigen 1
(HTA-1)

[22,23]

which

is

expressed

by

cortical

thymocytes

[24,25].

In the further biochemical characterization of the CDIa

molecule several similarities to class I MHC protiens have been
noted.

CDIa and class i MHC molecules share serologically

defined epitopes [26] and have biochemically similar structures
including three extracellular domains named a-1, a-2, and a-3
[26-35].

CDIa and class I MHC protiens both associate with (3-2

microglobulin through their a-3 domain [29-31], and both have
been

reported to

molecule [32,33].

associate with

the

CD8 thymocyte

surface

In addition, the predicted secondary structure
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of the a-1 and a-2 domains of CDIa is very similar to the antigen
binding pocket of HLA-A2, which is a well characterized class I
MHC molecule [27,28].

As a result of these similarities, it has

been argued that CDIa represents a novel type of class I MHC
molecule [30,31], and as such may be involved in the presentation
of antigen to T-cells [26-33].

While presentation of antigen by

CDIa has not been proven, CDIa does appear to be part of a
receptor site since
vesicles,

and

it is

internalized via coated

endosomes

mediated endocytosis [36].

in

ways

characteristic

pits,
of

coated
receptor

It is also intriguing that LC and

cortical thymocytes are the only cells expressing CDIa and are
the only nucleated somatic cells deficient in class I MHC protein
expression [37,38].
reciprocal

anatomic

The structural similarities, together with the
distribution

of

CDIa

and

class

I

MHC

molecules, suggests that these molecules may perform either
similar, or mutually exclusive functions.
While recent work has focused on the precise role of immune
function associated molecules such as CDIa expressed by LC, the
function of LC themselves has been studied and debated since
their discovery.

As mentioned above, Langerhans himself initially

believed that these cells were part of the peripheral nervous
system [1], however, in 1882 he published a short correction of
his original paper of 1868 stating "I am now convinced . . . that
my cells are in no way essential for nerve endings" [39].

He

appearently based this correction on the histological work of
Mojsisovics and Merkel [39].

Langerhans' retraction went largely

7

unnoticed, and little progress was made toward the understanding
of LC function for more than a century.
Silberberg

described

the

lymphocyte-like cells in
application

of mercury

apposition

only

in

LC

1973,

and

however,

mononuclear

man, within 4-6 hours of the topical
bichloride,

contact hypersensitivity [10].
identified

of

In

which

is

known

to

induce

Furthermore, this apposition was

subjects with

allergic reactions to

mercury

bichloride, and not in subjects with primary irritant reactions, or
no reaction to mercury bichloride [10,40,41].

In addition, it has

been shown that contact sensitivity to a specific allergen can be
passively

transferred

by

lymph

node

cell

suspensions

from

sensitive to naive animals, and after dermal challenge with the
allergen, allergen bearing LC are found in lymph nodes of the
formerly naive animals [42,46].

Subsequent studies have proven

that LC can pick up antigen in the skin and carry it by way of
dermal

lymphatics,

to draining

findings firmly established an

lymph

nodes

immunological

[42-45].

These

role for LC and

strongly suggested that they may be involved in the presentation
of antigen to T-cells in lymph nodes.

In vivo proof of the antigen

presenting capacity of LC has accumulated from two other types
of observations as well.

In the first, it has been noted that

cutaneous surfaces devoid of LC do not support the development
of contact hypersensitivity after application of allergen [59-61].
In the second, LC deficient allografts such as tape-stripped skin
and cornea,

have been

shown to

alloimmune reactions [62-65].

lack the ability to

induce

More recently Cruz et al have
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reported

that

intravenously

infused

murine

LC

migrate

preferentially to skin where they can participate in the induction
of contact hypersensitivity [66].

In summary it is known that LC

originate in bone marrow, migrate to the epidermis where they
pick up antigen, and then transport antigen to draining lymph
nodes where they stimulate antigen specific immune responses.
The in vivo findings discussed above have been supported by
many studies of LC in vitro.

While epidermal LC do not survive in

culture for more than 6 to 9 days [69,70], recent interest has
focused on

marked changes in their observed phenotype and

function

vitro.

in

As

mentioned

above,

freshly

isolated

LC

express class II MHC [8,9] and CDIa surface antigens [21] and
little

or

no

maintained

class
in

I

MHC

culture

protein

for 2 to

3

[17-19].

However,

days,

show

LC

when

increased

expression of class I MHC and class II MHC antigens, while losing
CDIa positivity [71,72].

These phenotypic changes have been

related to changing functional activities of LC such as processing
antigen in the skin, and then presenting it in draining lymph nodes
[75].

Studies of human LC have shown that they can substitute for

macrophages
tuberculin

in

presenting

protein,

a

variety

of

antigens

such

as

herpes simplex virus proteins, trichophytin,

and nickel sulfate to autologous T-cells from sensitized donors
[47-50].

In addition, studies in both animals and humans have

shown that LC enriched epidermal cell suspensions, but not LC
depleted suspensions, induce a strong proliferative response from
resting

allogeneic

T-cells

in

9

mixed

epidermal-lymphocyte

reactions (MELR's) [50,51].

This stimulation has been shown to

occur in an MHC class II restricted fashion [52-53].

Since it is

the CD4 glycoprotien which recognizes antigen complexed to MHC
class II molecules [54-58], this stimulation probably involves
CD4+ cells, such as T-helper lymphocytes.

Functional studies

comparing the abilities of freshly isolated and cultured murine LC
have shown that freshly isolated LC actively present protein
antigens such as myoglobin to specifically primed T-cells, but
are relatively poor stimulators of allogeneic T-cells in MELR's
[73].

However, after culture for two to three days, murine LC

present protein antigen only very weakly, while their ability to
stimulate allogeneic T-cells increases roughly ten fold [73-75].
Similar studies by Teunissen and Romani have shown that the
ability of human LC to stimulate allogeneic reactions increases
two to ten fold after 3-5 days of culture [76,71].

Teunissen has

suggested that this increased ability to stimulate allogeneic Tcells may be due to increased MHC class II protein expression on
cultured

LC

[76],

however,

the

relationship

between

the

phenotypic and functional changes seen in cultured LC has not
been clearly defined.

All of the above observations from in vitro

and in vivo studies have led to the conclusion that LC are the
primary antigen presenting cells of the skin [67], and have
implicated LC as the most peripheral component of a unique
collection of cells and lymphoid organs called skin-associated
lymphoid tissues (SALT) that function as a group to perform the
specialized immune requirements of the skin [68].

•

Most recently, reports from work in murine systems have
shown that epidermally associated cytokines such as InterleukinI (IL-1), Granulocyte Macrophage-Colony Stimulating Factor (GMCSF), and Tumor Necrosis Factor-a (TNF-a), may influence LC
phenotype and function in vitro [69,77-79].

Specifically, Witmer-

Pack and collegues have shown that the addition of GM-CSF to
murine LC cultures has three effects over a 2-3 day culture
period:

cell viability is increased, LC become larger and more

dendritic,

and

their

stimulatory

increases 10 to 20 fold [77].

ability

for

allogeneic

T-cells

Similar work by Heufler et al using

several measures of stimulatory ability has comfirmed that it is
the direct effect of GM-CSF, and not simply improved viability
which leads to this enhancement in function [69].

In addition,

they showed that a combination of IL-1 and GM-CSF added to
murine

LC

cultures

leads

to

a

2

fold

further

increase

in

stimulatory capacity compared to LC cultured with GM-CSF alone
[69].
vitro,

TNF-a has been shown to enhance murine LC viability in
however,

TNF-a

treated

LC

stimulators of allogeneic T-cells [78].

remain
In

relatively

poor

phenotypic studies

Belsito et al have recently reported an enhancement of MHC class
II antigen expression by murine LC cultured in the presence of
either IL-1, GM-CSF or TNF-a [79].

Evidence of the effects of

these cytokines on human epidermal cells is scarce.

However,

Walsh et al report that IL-1 can induce CDIa expression on human
gingival epithelial cells [80].

All of these in vitro findings may

have important implications for the regulation of LC phenotype

and

function

in

vivo since it is known that cultured

keratinocytes produce IL-1 [79], and GM-CSF [82].
shown

recently that TNF-a

human

It has also been

message is detectable in

epidermal mRNA preparations [Longley et al in preparation].

human
When

injected intraveneously in mice, TNF-a targets specifically to the
skin [83], indicating the presence of receptors for TNF-a, and
suggesting that this cytokine plays a role in the biology of the
skin.

To determine how these cytokines affect the phenotypic

characteristics of human

LC

in vitro, we cultured purified LC

from normal human skin with IL-1, GM-CSF, and TNF-a, and
compared CDIa expression with untreated cultures.

In a similar

set of experiments we cultured human cortical thymocytes, which
also express CDIa, with the same cytokines and measured both
CDIa and class I MHC expression.

To assess the functional

effects of these cytokines, we compared the ability of treated
and untreated human LC to stimulate proliferation of allogeneic
T-cells, and attempted to block this proliferation with a variety
of

monoclonal

antibodies.

T-cell

stimulation

was

measured

through standard techniques of the MELR.

Materials and Methods

Isolation of Langerhans Cells
Normal human skin was obtained from elective plastic surgery
procedures and trimmed to the level of the papillary dermis.

Skin

was then incubated in Tyrodes solution with 10 mg/ml Dispase
(Boerhinger Mannheim, W. Germany) overnight at 4°C and then at
37°C for 20 minutes.

Dispase is a neutral protease which

selectively digests fibronectin

and type

IV collagen

[87] thus

allowing sheets of epidermis to be easily separated from the
dermis and assuring that only epidermal cells were

studied.

Epidermal sheets were then incubated at 37°C for 15 minutes in
0.125% Trypsin (Gibco Labs Inc., Grand Island, New York), vortexed
at low speed for 1-2 minutes and filtered through three layers of
sterile gauze.

The resulting epidermal cell suspension was then

layered over Histopaque-1077 (Sigma Diagnostics, St. Louis, Mo.)
at 4°C and centrifuged at 300 g's for 20 minutes.

Cells remaining

at the interface were collected, viability assessed by trypan blue
exclusion, and the percentage of cells expressing CDIa measured
by flow cytometry after staining with OKT6 monoclonal antibody
(from ATCC hybridoma # CRL 8020), and FITC conjugated goat
anti-mouse secondary antibody (Becton Dickinson, Mountain View,
CA).

This technique reliably yielded 97-100% living cells and a

maximum of 30% CDIa positivity.

In some LC experiments, a

further enrichment for CDIa positive cells was carried out by
staining

interface cells with an

anti-class

antibody (anti-HLA-A,B,C from the W6/32

I

MHC

monoclonal

hybridoma ATCC #

HB95) and counterstaining with an iron conjugated goat anti¬
mouse secondary antibody (Advanced Magnetics Inc., Cambridge,
MA.).

These cells were then precipitated to a magnetic plate

(Advanced Magnetics Inc.) and nonmagnetic cells were washed

•

!

from the plate.

This procedure increased the percentage of GDI a

positive

from

cells

a

maximum

of

30%

with

Histopaque

enrichment alone, to a maximun of 50%.

Langerhans Cell Cultures
Cells were then plated out at 1X10® cells/ml in 24 well flat
bottomed plates (Corning Glass Works, Corning, NY) in RPMI 1640
(Gibco Labs Inc.), 10% defined fetal bovine serum (HyClone Labs
Inc.,

Logan,

UT), 1% Penicillin G/Streptomycin/Amphotericin

B

(Gibco Labs Inc.) and lOng/ml of recombinant human IL-1, GM-CSF
(gift of Dr. Steven Gillis, Immunex Corp., Seattle, WA.), or TNF-a
(courtesy of Dr. Thomas Kupper, Yale School of Medicine, Dept of
Dermatology) versus control.

Viability and GDI a positivity were

assessed on day .0, 2, 3, and 5 of culture by flow cytometry.

Thymocyte

Isolation

Thymus glands were obtained from newborn infants during the
course of corrective cardiac surgery, minced, suspended in RPMI
1640 (Gibco Labs Inc.), and filtered through sterile gauze.
resulting

cells

were

purified

on

a

Histopaque-1077

The

(Sigma

Diagnostics) gradient as for LC, and then cultured at 1X107
cells/ml with conditions and cytokines as for LC.

In a series of

depletion experiments, GDI a, or class I MHC positive cells were
depleted from thymus gland cell suspensions before culture using
the appropriate monoclonal antibody, and the magnetic technique
detailed above.

In all cultures, the percentage of cells expressing

,

CDIa and class I MHC was determined on day 0 and 8 by flow
cytometry.

Preparation of T-cells
Resting allogeneic T-cells for mixed cultures were prepared
as follows: Peripheral mononuclear cells (PMN) were obtained
from the blood of healthy volunteers through Histopaque density
gradient centrifugation as above.

PMN were then suspended in

RPMI 1640 (Gibco Labs Inc.), 10% defined fetal bovine serum
(HyClone Labs Inc.), 1% Penicillin G/Streptomycin/Amphotericin B
(Gibco Labs Inc.) at 1X107 cells/ml and monocytes allowed to
adhere to a plastic culture flask (Corning Glass Works) for 3-12
hr.s.

Medium containing nonadherent cells (lymphocytes) was

then decanted and the cells stained with an anti-class II MHC
protein antibody which reacts with HLA-DR, DP, (and possibly DQ)
framework determinant produced by the IVA12 hybridoma (ATCC
#HB 145).

Resting T-cells were then negatively selected with

the magnetic procedure described above.

This procedure reliably

yielded a cell suspension of 94-97% T-cells as assessed by
expression of T-cell receptor associated antigen (CD3) by flow
cytometry.

Mixed Epidermal Cell-Lymphocyte Cultures
Epidermal cells were prepared and cultured as above except
that they were plated out in triplicate over a range of 0-3000 LC,
in 200 microliters per well, in 96 well round bottomed plates

(Corning Glass Works).

The culture medium was the same as for

LC cultures, with either GM-CSF, IL-1, or TNF-a at 10 ng/ml.

On

day 3 of culture (72 hr.s), plates were centrifuged for 5 minutes
at 300 g and the culture medium replaced with medium containing
10$ purified allogeneic T-cells without cytokines.
epidermal cell-lymphocyte cultures were then

These mixed

incubated for 4

more days, pulsed with 1 microCurie of 3H-Thymidine

(Amersham

Inc., UK) per well, harvested 16 hr.s later and counts per minute
(CPM's) assessed with an LBK scintillation counter.

Blocking Studies
MELR's were performed as above, however monoclonal
antibodies to either class I MHC (anti-HLA-A,B,C, produced by the
hybridoma ATCC # HB95), class II MHC ( ATCC # HB145), or CDIa (
ATCC # CRL8020) were added to each set of cultures at the time
of T-cell

addition.

T-celi stimulation was

measured by ^H-

thymidine incorporation as above.

Statistical Analysis of Results
For LC cultures, experimental and control mean values with
standard errors were calculated and compared using the Student's
t-test.

For thymocyte cultures

all

experimental

values were

expressed as percents of control with control values set to 100%.
Averages and standard errors of experimental values were then
calculated and compared using a one way analysis of variance

(ANOVA).

In MELR's experimental and control means and standard

errors were calculated and compared using an ANOVA as above.

Results

Langerhans Cell Cultures
Viability of epidermal cells decreased in a predictable manner
such that nearly all cells were dead by trypan blue exclusion by
day 6 (Figure 1).

After 2 days of culture, GDI a expression among

viable cells in medium alone, GM-CSF,

IL-1, and TNF-a had

dropped from 30% upon isolation to 12.4%, 13.5%, 13.0%, and
11.4% respectively.

By day 5 of culture, CDIa expression among

control cells had dropped to 9.75±/l.2%, while TNF-a and IL-1
cultured

cells

respectively.

were

11.4+.1.2%

and

14.5±,Q.4%

positive

However, only 4.2+0.3% of GM-CSF cultured ceils

were CDIa positive

by day 5

(Figure 2).

IL-1

significantly

prolonged the expression of epidermally associated CDIa antigen
compared

to

untreated

cultures

(p=0.02),

while

significantly decreased CDIa expression (p=0.01).

GM-CSF

TNF-a did not

significantly alter CDIa expression in any cultures.

Thymocyte Cultures
The percentage of cells expressing CDIa or class I MHC
antigens after 8 days was determined after culture with the
indicated

cytokines.

The

number of cells

expressing

either

antigen in cytokine treated cultures was divided by the number of
cells expressing the same antigen in untreated cultures and the
resulting value multiplied by 100 to give the percent of control
cells expressing CDIa or class I MHC antigen.

Figure 3 shows the

mean values obtained from 5 such experiments.

The percentage of

cortical thymocytes expressing CDIa on day 8 was 124+12.7%
(TNF-a), 157±33% (IL-1), and 78+7.4% (GM-CSF) of control, while
the percentage of cells expressing class I MHC was 109+12%,
92±8.0%, and 148+34% of the control cultures respectively.

Thus

GM-CSF treatment was associated with accelerated loss of CDIa
expression from thymocyte cultures (p=0.03), and increased class
I

MHC expression

(p=0.02), compared to control.

IL-1

was

associated with effects opposite to those of GM-CSF, maintaining
the percentage of cells expressing CDIa above control (p=0.01)
and decreasing the percentage of cells expressing class I MHC,
however this effect was not significant (p=0.6).

TNF-a showed no

significant effect on either CDIa or class I

MHC expression,

however the small changes it did cause were similar in trend to
those of IL-1.
In a well known model of surface antigen expression during
thymocyte maturation, very early thymocytes are thought to be
CDIa negative/class

I

MHC positive,

but during differentation

become CDIa positive/class I MHC negative.

These cells again

become CDIa negative/class I MHC positive as they mature fully
and exit the thymus [37].
population

of

CDIa

There is also a small, well documented

negative/class

I

MHC

negative

(double

negative)

thymocytes which

may

represent cells

between the major populations listed above [37].

in

transition

In order to more

clearly define the effects of cytokines on surface antigens at
various

points

along

this

linear

differentiation

pathway,

we

performed the same experiments with thymocyte populations that
had been depleted of CDIa and class I MHC positive cells as
detailed above.
Figure 4 shows the result of experiments in which CDIa
positive

cells

suspensions

were

prior

magnetically

to

culture.

In

depleted
these

from

thymocyte

experiments

CDIa

expression was 108±3.8% (TNF-a), 146±16% (IL-1), and 64±6%
(GM-CSF) of control, while class I MHC expression was 139+12%,
220±_17%, and 96^8.8%,

respectively.

Therefore,

GM-CSF

prevented CDIa expression by CDIa negative/class I MHC positive
cells (p=0.01).

However, GM-CSF had no effect on class I MHC

expression in this population of thymocytes (p=0.8).

This finding

implies that GM-CSF may either block the maturation of CDIa
negative/class I MHC positive cells to the CDIa positive/class I
MHC negative phenotype, or accelerate development of the most
mature CDIa negative/class I MHG positive thymocytes.

In CDIa

depleted

of

cultures,

IL-1

increased

the

percentage

cells

expressing CDIa compared to control (p=0.03), an effect opposite
to

that

of

GM-CSF,

and

unlike

undepleted

cultures,

IL-1

significantly increased the expression of class I MHC (p=0.08).
These

effects

could

be

explained

if

IL-1

was

a

general

accelerator of thymocyte maturation moving cells both into and

out of the CDIa positive/class I MHC negative state.
explanation could be that IL-1

Another

increases the antigen expression

and/or viability of thymocytes without effecting maturation.

In

this case, the increased percentage of cells expressing these two
antigens could be explained by larger numbers of viable cells
expressing antigen, or more cells expressing detectable levels of
antigen.

TNF-a again produced insignificant changes in antigen

expression in these cultures.
In a final set of thymocyte experiments, class I MHC positive
cells

were

depleted

prior

to

culture

yielding

populations that were 80-90% CDIa positive,

thymocyte

and containing

small numbers of CDIa negative/class I MHC negative cells.
results of these experiments are shown

in figure 5.

The
CDIa

expression among thymocytes was 126±8.4% (TNF-a), 152+17%
(IL-1), and 94+3.9% (GM-CSF) of control, while class I MHC
expression

was

respectively.

122^8.6%,

108^4, and 180±4.0% of control,

In these experiments IL-1

significantly increased

the percentage of ceils expressing CDIa (p=0.03), and GM-CSF
significantly increased class I MHC expression (p=0.08), while no
other results were significant.

These findings lend additional

support to the hypothesis that GM-CSF accelerates the maturation
of

CDIa

positive/class

negative/class

I

MHC

I

MHC

positive

results

suggest that

IL-1

CDIa

negative/class

I

may
MHC

negative
phenotype.

In

to

the

CDIa

addition

these

influence

the differentation

negative

cells

positive/class I MHC negative phenotype.
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cells

to

the

of

CDIa

'

To summarize the results of these three sets of experiments,
GM-CSF tended to decrease CDIa expression compared to control
in undepleted, CDIa depleted, and class I MHC depleted cultures,
however the effect in this latter set of cultures was small and
not statistically significant (p=0.6).

IL-1

while TNF-a

increased CDIa in all

three sets

of cultures,

had no effect on CDIa

expression.

GM-CSF increased class i MHC expression compared

to controls in undepleted and class I MHC depleted cultures, but
not in CDIa depleted cultures.

This is exactly the opposite effect

and pattern of significance compared to GM-CSF's effect on CDIa.
IL-1

increased class I MHC expression only in CDIa depleted

cultures, and as in studies of CDIa, TNF-a had no effect on class I
MHC expression.

This complex pattern of results is summarized

in table 1.
In both thymocyte and LC cultures, GM-CSF tended to decrease
CDIa expression compared to control, while IL-1 increased CDIa
expression.

TNF-a had no effect on CDIa expression in either

thymocyte or LC cultures.
CSF

tended

decreasing

to

In undepleted thymocyte cultures GM-

reciprocally

CDIa

effect

expresion

while

CDIa

and

class

enhancing

class

I

MHC,
I

MHC

expression.

Functional Studies of Langerhans Cells
As seen in figure 6, LC precultured for 72 hours with GM-CSF
were more potent stimulators of allogeneic T-cell proliferation
than cells cultured with IL-1, TNF-a or no cytokine.
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Specifically,

GM-CSF treated LC produced significantly more allogeneic T-cell
proliferation than LC cultured under all other conditions. This
was true at all doses of LC tested (p<0.02), except at 300 LC
where proliferation was the same as control (p=0.5).
with IL-1

LC cultured

showed no significant increase in proliferation at any

dose tested, while TNF-a treated LC produced less proliferation
than control, but only at a dose of 900 LC (p=0.05).

Figure 7

shows the results of subsequent experiments concentrating on
the effect of GM-CSF, and extending the doses of LC used to a
maximum of 3,000.

In these cultures GM-CSF treated LC were

more potent stimulators of allogeneic T-cells than control cells
at p<0.01 for all doses of LC tested except at 250 LC where
p=0.05.

Also of note is that there was no significant difference

in the amount of T-cell proliferation seen in GM-CSF and control
cultures in which there were no LC even though these wells were
treated as if they did contain LC during the 72 hour pretreatment
period.

This observation precludes the possibility that it is the

presence of contaminating GM-CSF that is solely responsible for
the enhanced T-cell stimulation seen in GM-CSF treated cultures.
In addition, there was a direct relationship between the number
of LC in culture and the level of T-cell proliferation, regardless
of the culture conditions, indicating that GM-CSF augments LC
ability to stimulate allogeneic reactions on a cell by cell basis.

Blocking Studies
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Figure 8 shows the results of MELR's in which all Langerhans
cells were pretreated for 72 hours with GM-CSF.

At the time of

T-cell addition, however, antibodies reactive to either GDI a,
class I MHC, or class II MHC were added to culture.

In these

cultures the addition of anti-GDI a had no effect on allogeneic Tcell stimulation.

In cultures treated with anti-class II MHC,

however, T-cell stimulation was inhibited in cultures containing
1500 LG or less (p<0.02), while at higher doses of LG, addition of
anti-class

II

MHC

antibody

did

not

alter

levels

of

T-cell

stimulation.

Most interestingly, when anti-class 1 MHC antibody

was

to

added

culture

there

was

an

inhibition

in

T-cell

stimulation at all doses of LG tested (p<0.02).

Discussion

The study of LG in vitro has long been hampered by difficulties
in purifying large numbers of intact cells from the epidermis.
modifying

the

methods

used

by

a

variety

of

By

different

investigators, we have developed a technique for rapidly isolating
human LG without altering their surface phenotype.

Many methods

for LG isolation involve long incubations of skin with the enzyme
trypsin to obtain epidermal cell suspensions [84], followed by LG
enrichment by a variety of techniques.

These include "panning"

[77],

[76],

density

gradient

centrifugation

activated cell sorting [85].

and

fluorescence

While these techniques yield very
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pure populations of LC, they are often long, expensive, and plagued
by the uncertain effects of trypsin on LC surface proteins.
Most recently Hanau et a! have described an immunomagnetic
selection technique where by epidermal cell suspensions are
stained with a GDI a reactive antibody, and then counterstained
with a secondary antibody that is conjugated to small iron beads.
Cell suspensions are then precipitated to a magnetic plate and
GDI a negative cells washed from the plate.

This procedure

results in a very pure population of LC that can be obtained
quickly and economically [86].

However, unless the amount of

magnetic material used is carefully titrated, the resulting LC are
rendered useless for in vitro functional studies due to the iron
beads bound to their surface.

By incubating skin with the enzyme

Dispase which is known to digest only fibronectin and type IV
collagen [87], we have obtained relatively unmodified epidermal
cell suspensions.

These suspensions are then enriched for LC by a

combination of density gradient centrifugation, and a negative
immunomagnetic
altering LC.

selection

that depletes

keratinocytes without

This technique is detailed above and routinely yields

epidermal ceil suspensions 30-50% GDI a positive in 4 to 5 hours.
Our phenotypic studies of both LC and cortical thymocytes
suggest that expression of GDI a antigen can be altered by IL-1,
and GM-CSF.

In particular, GM-CSF tended to accelerate the loss

of GDI a from LC and thymocyte cultures, while IL-1
it.

maintained

The effects of these two cytokines on class I MHC expression

in thymocyte cultures seemed to be the opposite of their effects
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on GDI a.

That is to say, GM-CSF maintained class I MHC

expression above control, while IL-1
nondepleted thymocyte cultures.

accelerated its loss from

These results lend credence to

the notion that GDI a and class ! MHC are reciprocally regulated
and are consistant with the observation that GDI a and class I MHC
are reciprocally expressed in vivo [38,39].

Moreover, because

these cytokines can be produced by keratinocytes [79,82] these
observations suggest that GM-CSF and IL-1 may play similar roles
in vivo.

While we have shown that the loss of GDI a antigen by

human LG can be modulated by IL-1 and GM-CSF, for technical
reasons we were unable to study the effects of these cytokines
on LG MHG class I expression.

As mentioned above however, a

recent study by Romani et al, has shown that the loss of GDI a
expression by human LG is accompanied by a rapid increase in
both class I and class II MHC expression [71].

There remains

however, no published observations of the effects of epidermally
associated cytokines on class I MHC expression by LG in vitro.
Our phenotypic results are consistant with previous work in
murine systems showing

that loss of GDI a analogs can

accelerated in vitro by exogenous GM-CSF [69,77].

be

These studies

also report that GM-CSF enhances the viability of murine LG in
vitro.

In

our study

viability

among

there was

cells cultured

with

no

significant difference

IL-1,

control as assessed by trypan blue exclusion.
an

GM-CSF,

TNF-a, or

This may represent

important difference between the behavior of human

murine LC in vitro.

in

and

We are aware of only one study of the effects
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of cytokines on human LC; Walsh et al have shown that culturing
GDI a depleted human gingiviai cells with IL-1 induces expression
of GDI a in these cultures [80],

Our data support this finding in

both human LC and human thymocyte cultures and, as discussed
below, we have shown that CDIa depleted thymocytes can be
induced to express CDIa after treatment with

IL-1,

much as

gingiviai cells did in Walsh's study.
In our initial experiments on the effects of GM-CSF, IL-1, and
TNF-a on CDIa and class 1 MHC expression by unfractionated
thymocytes,

we

found

that

GM-CSF

was

associated

with

decreased expression of CDIa and increased expression of class I
MHC, while IL-1
CDIa.

The

was associated with increased expression of

significance

of these

effects

during

thymocyte

differentiation are unclear, however, due to the complexity of the
thymic microenvironment.

It is known, however, that thymocyte

differentiation takes place in a linear fashion with
surface antigen expression.

respect to

In particular, it is believed that bone

marrow derived prothymocytes enter the thymus where they are
initially

CDIa

negative/class

I

MHC

positive.

During

differentiation, they become CDIa positive/class I MHC negative,
and finally as they develop into mature T-cell subsets, they once
again become CDIa negative/class ! MHC positive [37].
isolate

subsets

of

thymocytes

at

various

points

In order to
along

this

pathway and more precisely determine the effects of cytokines
during thymocyte development, we performed the CDIa and class I
MHC depletion experiments detailed above.
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While the results of

these depletion experiments must be interpreted with caution,
the pattern of effects seen indicates that GM-CSF may prevent
GDI a expression by ceils of the GDI a negative/class I

MHC

positive phenotype, and enhance expression of class I MHC by
cells of the GDI a positive/class I MHC negative phenotype.

In

general, this pattern suggests that GM-CSF may be involved in the
reciprocal regulation of GDI a and class I MHC molecules.

When

explained in the context of the thymocyte differentiation model
mentioned above, these results imply that GM-CSF may either
block the development of the GDI a positive/class I MHC negative
phenotype,

and/or accelerate

the

development

of

the

CDIa

negative/class I MHC positive phenotype.
The effects of 11-1 on CDIa and class I MHC expression in
thymocyte cultures are in general opposite to those of GM-CSF, in
that IL-1 increases CDIa expression by cells expressing class I
MHC (CDIa positive/class S MHC negative and CDIa negative/class
I MHC positive thymocytes), however IL-1 also increases CDIa
expression by CDIa positive/class I MHC negative thymocytes.
IL-1 has no effect on class I MHC expression unless CDIa positive
cells are depleted, in which case IL-1
expression.

increases class I MHC

The observed effects of IL-1 on thymocyte surface

antigen expression are hard to explain within the context of the
thymocyte differentiation model discussed above, because IL-1
tended to increase both CDIa and class I MHC expression by CDIa
negative/class I MHC positive thymocytes.
accounted

for

if

IL-1

had
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a

This effect could be

significant

effect

on

CDIa

negative/class I MHC negative thymocytes in transition between
the major populations, or if IL-1 enhances the antigen expression
and/or viability of thymocytes in vitro, in which case more cells
may appear to be expressing both antigens compared to control.
We

are

currently

selected

GDI a

performing

experiments

negative/class

I

MHC

using

magnetically

negative thymocytes to

explore the effects of IL-1, as well as GM-CSF and TNF-a on this
population of ceils.
Also of note is that TNF-a produced only weak changes in GDI a
and

class

significant.

I

MHC

expression

which

were

not

statistically

This is not suprising because while TNF-a production

has been shown in human thymocytes [92], its effects may have
been obscured since TNF-a can induce GM-CSF production in a
variety

of

cell

types

[91].

Thymocyte

differentiation

is

influenced by a variety of factors including cell-cell contact [93]
and cytokines released by epithelial and mesenchymal cells [94],
and while our studies

provide

only clues to

unravelling

the

complex environment of the thymus, they do show that GDI a in
both skin and thymus is similarly effected by GM-CSF and IL-1
thus

supporting

a

global

role

for

these

cytokines

in

immunoregulation.
It is becoming increasingly clear from our work and that of
others that IL-1 and GM-CSF are regulators of immune function
associated molecules such as MHC class I and GDI a in vitro.
Since these cytokines are made by normal human keratinocytes in
vitro

[81,82]

it is possible that they play some role in the
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regulation of human LC in vivo.

In addition, IL-1 production has

been demonstrated in thymic epithelial cells [88], and GM-CSF
production

by

thymic

possibility

that

these

nonlymphoid
cytokines

cells

are

[89]

also

raising

involved

the

in

the

regulation of antigen expression by thymocytes in the thymus.
While evidence of cytokine production by cells of the skin and
thymus supports the conclusion that the phenotypic regulation we
have described in vitro may be important in vivo, this evidence
also presents a problem in the interpretation of our data.

For

example, our LC cultures are typically contaminated with >5 0%
keratinocytes, and any culture obtained from thymus gland will
invariably contain contaminating epithelial cells and fibroblasts.
It

is

known

that

keratinocytes

IL-1

[90],

can

while

induce

production

of GM-CSF in

TNF-a can induce its production in

fibroblasts, smooth muscle ceils, and endothelial cells [91].

Thus

the direct effect of exogenous cytokines may be hard to assess
and it may be that our best attempts to create simple in vitro
systems
signalling

still

result

molecules,

in

a

complex

interaction

as is the case in

vivo.

of

cells

and

Despite these

concerns, it seems clear that epidermally associated cytokines
influence

the

expression

of

immune

molecules on human LC and thymocytes.

function

associated

As discussed below,

these cytokines also influence the functional abilities of LC in
vitro.
It has been known for some time that the ability of human
Langerhans

cells

to

stimulate
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allogeneic

T-cells

increases

dramatically after 2-3 days in culture [71,76], and recent murine
studies have shown that GM-CSF can accelerate the development
of this ability [69,77].
human LC.

We have extended this observation using

In particular we have shown that human LC precultured

with GM-CSF for 72 hours are 2-3 times more potent than control
cells in the stimulation of allogeneic T-cells.

While this finding

may have been predicted from murine studies, it is important in
light of the differences noted between murine and human immune
systems.

These differences have been demonstrated by the fact

that human epidermis lacks a cell equivalent to the Thy 1 positive
dendritic
epidermis.

T-cells

which

represent

2-5%

of

cells

in

murine

Since keratinocytes can produce GM-CSF [82], it is

possible that the exogenous GM-CSF used in these experiments
merely augmented endogenous GM-CSF in the cultures, thus
accelerating both the phenotypic and functional changes.
functional

studies

with

TNF-a and IL-1

Our

showed slightly lower

levels of T-cell proliferation than control, however these results
were not statistically significant.

It is possible that endogenous

GM-CSF was subtracting from the magnitude of these cytokines'
effects.

We are therefore planning blocking studies using anti-

GM-CSF antibodies to further isolate the effect of IL-1, TNF-a,
and endogenous GM-CSF on LC in vitro.

It is not clear from our

studies whether the increased stimulatory capacity of GM-CSF
cultured cells represents a change in LC physiology or is mediated
by phenotypic changes such as increased class I MHC or decreased
CDIa expression.

It is clear that the effect is not due to changes
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in viability of LC in culture since viability was the same in all of
our experimental and control groups.

We were concerned that GM-

CSF might cause increased allogeneic T-cell stimulation by a
direct effect on T-cells.

This is an unlikely explanation for our

results for several reasons.

For one, LC were carefully washed of

cytokine containing medium before addition of allogeneic T-ceils.
Second, wells in which there was culture medium and GM-CSF but
no LC did not show increased T-cell proliferation compared to
wells in which there was culture medium, no GM-CSF, and no LC.
This finding precludes the possiblity that it was the direct effect
of GM-CSF that was solely responsible for the increase in T-cell
proliferation

seen.

It

is

theoretically

possible

that

a

small

amount of residual GM-CSF stimulated proliferation of allogeneic
T-cells, but since there was probably some endogenous GM-CSF in
all cultures, we doubt that it could have had a significant effect.
Another far less likely possibility is that GM-CSF increases
the ability of keratinocytes to stimulate allogeneic T-cells.
studies

have

shown

that

depleting

LC

from

Many

epidermal

ceil

suspensions renders these suspensions all but devoid of the
ability

to

stimulate

ability

of

injected

T-cells
LC

and

[50,95].

Studies

keratinocytes

to

comparing

prime

the

allogeneic

reactions in mice show that LC are >10^ times as potent as
keratinocytes at priming allogeneic reactions to subsequent skin
allografts

[96,97].

keratinocytes

to

It

appears

stimulate

then

allogeneic

that

reactions

the

ability

of

is

limited

at

best, and it is therefore unlikely that they are capable of inducing

31

the high levels of T-cell proliferation typically associated with
LC, even under the influence of GM-CSF.
It is reasonable to say then that the increased stimulation
seen in our GM-CSF treated cultures is probably due to a direct
effect on

LC.

The

mechanism of this effect has

discerned in either human or murine systems.

not been

It is attractive to

postulate that this increased functional ability is in some way
related to the changes in surface phenotype associated with GMCSF pretreatment, and our blocking studies are an attempt to
explore this possibility.
In these blocking experiments all LC used were pretreated
with GM-CSF in order to compare the effects of the three blocking
monoclonal antibodies used (anti-class I MHC, anti-class II MHC,
and anti-CDIa) to GM-CSF treated LC alone.

As predicted from

many in vitro and in vivo studies of antigen presentation by LC,
anti-class

II

MHC

blocked T-cell

stimulation

in

a statistically

significant way, even though the effect was saturated at higher
doses of LC.

The anti-class II MHC antibody used in these

cultures was a filtered, titered hybridoma supernatant, and the
precise concentration of antibody was unknown.

It is possible,

therefore, that high numbers of LC overcame the class IS MHC
blockade, since the amount of anti-class IS MHC supernatant used
was constant throughout our cultures.
An interesting and unpredicted finding from these blocking
experiments

is

the

significant decrease

in

T-cell

stimulation

seen in anti-class I MHC treated cultures at all doses of LC
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tested.

This is a novel observation in MELR's using LC, and we are

unaware of other workers in animal or human systems reporting
or even attempting this type of blockade.

It is possible that the

anti-class ! MHC antibody added to cultures is producing this
blockade in an idiosyncratic or nonspecific fashion, however the
other more interesting possibility is that LC in vitro are involved
in allogeneic T-cell stimulation in a non-class II MHC restricted
fashion.
the

There is some indirect evidence to support this notion in

findings

of

Romani

et

a!

which

show

that

human

LC

dramatically increase their expression of MHC class I surface
antigens after 2 to 4 days in vitro, while increasing their ability
to stimulate allogeneic reactions [71].
Finally, the addition of anti-CDIa monclonal antibody had no
effect on the levels of T-ceii stimulation seen when comapared
to control cultures without blocking antibodies.

CD1 a has many

similarities to MHC class I molecules as discussed above [26-35],
and it has been speculated that CDIa may then have a function
similar to class I MHC molecules, namely antigen presentation to
CD8

positive

associated

T-cells

with

[57,97].

CD8+

T-cells

are

suppressor and cytotoxic functions

their proliferative

response to stimulation

generally
[54],

and

is generally smaller

and shorter in duration than that of CD4+ cells [99].

CD8+ cells

are also difficult to grow because they often kill the cells that
stimulate them

[100], and have stringent growth

including the presence of IL-2 [101].

requirements

As a result, stimulation of

CD8+ cells by LC bearing CDIa could easily be overlooked in
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MELR's

containing

large

numbers

of

CD4+ cells.

If such

stimulation were obscured, blockade of stimulation would surely
be obscured as well.
stimulation

by

Thus, the lack of blockade of T-cell

anti-CDI a

antibody

in

our cultures

does

not

preclude the possibility that GDI a is functioning as an antigen
presenting molecule for a subset of CD8+ lymphocytes.
In order to explore the possibility of class I MHC ( or GDI a)
stimulation

of CD8+ cells in vitro, we are planning a series of

experiments using GM-CSF cultured LG and fractionated CD4+ and
CD8+ subsets of T-ce!ls in MELR’s.

In addition, these experiments

will use IL-2 in T-cell culture medium in order to amplify the
proliferative response of CD8+ cells [101].

These experiments

may shed additional light on the possibility of LG stimulating
allogeneic T-cel!s in a non-class II MHC restricted fashion.
results

from

proliferation

these
in

experiments

indicate that

allogeneic CD8+ T-cells.

LG can

Early
induce

This finding is a very

important piece of evidence in proving that LG stimulate the
immune system through circuits other than the MHC class II/CD4+
T-cell pathway.

However, more work is required to confirm this

very preliminary finding.

There is some evidence that LG present

antigen in a non-MHC class II restricted fashion in a recent study
by Porcelli et al.

In this study, the authors demonstrate the

specific recognition of GDI a by a CD4‘/GD8‘ (double negative)
cytotoxic T-cell line which causes direct lysis of GDI a bearing
cells [102].

Furhtermore, this lysis can be blocked with anti-

GDI a monoclonal antibodies [102].
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The GDI a positive cells used

in this study, however, were the MOLT-4 thymic leukemia cell
line and thus proof of non-MHC class II

restricted antigen

presentation by physiologic LC is still lacking.

While a great deal

of work is still needed to understand the regulation of LC and
their unique surface antigen CDIa, work like ours and Porcelli's
has begun to describe the regulation of the observed phenotype
and function of LC, and may eventually lead to a precise
understanding of the role of these cells in the immunology of the
skin.
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Nature 341:447-

Figure 1. viability of Langerhans cells in vitro as assessed on days
0, 2, 3, 5, and 6 of culture by trypan blue exclusion. There was no
difference in viability in cultures treated with IL-1, GM-CSF, TNF-a,
or control.

Figure 2. percentage of cells expressing CDIa surface antigen as
assessed by flow cytometry on days 0, 2, 3, and 5 of culture. By day
5 control cells were 9.75±1.2% CDIa positive, while GM-CSF treated
cells expressed significantly lower levels of CDIa (4.2^0.26%,
p=0.01), and IL-1 treated cells expressed significantly more CDIa
(14.45±0.04%, p=0.02). TNF-a did not produce a significant change in
CDIa expression (11.35+1.2%, p=0.5).

250

Figure 3. Undepleted thymocyte cultures. GM-CSF was associated
with decreased GDI a expression (78+7.4%, p=0.03), and increased
MHC I expression (148±34%, p=0.02).
IL-1 was associated with
increased GDI a expression (157^33%, p=Q.Q1), while all other
effects were satistically insignificant.

250

n % CDIa
E^l % MHCI

200

c

o

O

o

Figure

4.
MHC I depleted thymocyte cultures.
GM-CSF was
associated with increased MHC I expression (180+4.0%, p=0.008), and
IL-1 with increased CDIa expression (152±17%, p=0.03). All other
effects were insignificant.

250

Figure 5.
CDIa depleted thymocyte cultures.
GM-CSF was
associated with decreased CDIa expression (64±6%, p=0.01), IL-1
was associated with increased CDIa expression (146+16%, p=0.03),
and increased MHC I expression (22G±17%, p=0.08). AH other effects
were insignificant.

Figure 6. Langerhans cell/T-cell MELR. LC pretreated with IL-1
produced levels of T-cell proliferation unchanged from control, as
did LC pretreated with TNF-a (except at 900 LC where TNF-a
produced significantly less T-cell proliferation than control p=0.05).
GM-CSF pretreatment produced significantly increased levels of Tcell proliferation (p<0.02) except at 300 LC (p=0.5).

CPM 3H-Thymidine ± SEM
Figure 7. Langerhans cell/T-cell MELR focusing on GM-CSF. GM-CSF
produced increased levels of T-cell proliferation at p<0.01 at all
doses of LC tested except 250 where p=0.Q5. In wells in which there
were no LC there was no difference in the amount of T-cell
proliferation seen in control versus GM-CSF treated cultures (p=0.3).

Figure 8.
Langerhans cell/T-cell MELR in which all LC were
pretreated with GM-CSF.
At the time of T-cell addition, blocking
antibodies to either MHC I, MHC II, or CDIa were added to culture.
Anti-MHC II produced a significant reduction in T-cell proliferation
at 0-1500 LC (p<0.03), but no reduction at 2000-3000 LC (p=0.5).
Anti-MHC I produced a significant reduction at all doses of LC
(p<0.03). Anti-CDIa did not produce a significant change in T-cell
proliferation compared to control (p=0.5).
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